Navigation Links
Quark Pharmaceuticals Expands International Patent Protection for Compounds Targeting the RTP801 Gene
Date:10/26/2009

eting approvals and to generate commercial sales. We are vigilant about upholding our industry leadership position in siRNA R&D by protecting our pipeline with an aggressive and comprehensive approach to intellectual property generation and management. . We are also focused on broadening our intellectual property estate to further protect and enhance the value of our product pipeline."

About the PF-4523655 (RTP801i-14) Clinical Program

PF-4523655 (RTP801i-14) is a synthetic, siRNA molecule designed to inhibit the expression of Quark's proprietary target, RTP801. The product candidate is licensed to Pfizer on an exclusive worldwide basis. Quark discovered RTP801 using its BiFAR(TM) target discovery platform, which identifies clinically relevant genes and proteins that are critical to reversing a given disease phenotype when inhibited. The Company owns a family of patents covering the RTP801 gene and protein sequences, specific antibodies, and gene inhibition across different disease indications.

The ongoing Phase II study is a prospective, randomized, multi-center, dose-ranging study is designed to evaluate the safety and efficacy of PF-4523655 versus laser therapy in 160 patients with DME. In this study, patients are randomized to receive intravitreal injections of one of three dose levels of PF-4523655, or laser therapy. Therapeutic effect will be evaluated by assessing visual acuity and retinal morphology.

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel RNAi-based therapeutics. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's RNAi technology includes novel siRNA structures and chemistry providing Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability for non-invasive delivery
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
10. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
11. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... /PRNewswire-iReach/ -- VAPETEK™, Inc. has announced a new ... in portable vaporizers, which contains CBD, or cannabodiol. ... cannabidiol offers consumers a THC-free product made for ... technology. Photo - http://photos.prnewswire.com/prnh/20140711/126344 ... compounds which are currently known, two of which ...
(Date:7/11/2014)... July 11, 2014 The consumer marketing ... across industry sectors to better identify winning tools ... to engage with and understand consumers, as new ... make critical purchasing decisions. According ... LLC, one area where organizations can observe a ...
(Date:7/11/2014)... 11, 2014 Research and Markets ... Chinese Medical X-ray Film Industry Report 2014" report ... Global And Chinese Medical X-Ray Film ... on the current state of the Global medical X-ray ... The report provides a basic overview of the ...
Breaking Medicine Technology:VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2New Technologies Transforming Consumer Marketing Research Playbook 2Global and Chinese Medical X-ray Film Industry Report 2014 2
... WELLESLEY, Mass., Oct. 26 Coley,Pharmaceutical Group, Inc. ... company,has received a $3.0 million milestone payment from ... III clinical trial in,non-small cell lung cancer (NSCLC) ... adjuvant. In June 2007, GSK announced the ...
... at AACR-NCI-EORTC ... Symposium, ... MTAX: CTIC) and Systems Medicine, LLC (SM), a,wholly-owned subsidiary of CTI, ... 19th annual AACR-NCI-EORTC Symposium. "These studies show potential progress toward ...
Cached Medicine Technology:Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline 2Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline 3Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 2Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 3Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 4Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 5
(Date:7/13/2014)... According to a new market research report ... (processor, GPU, DSP, connectivity), Technology Node (45nm-5nm), Application ... Forecast and Analysis to 2014-2020", published by MarketsandMarkets, ... is expected to reach $61.70 Billion by 2020, ... to 2020. , Browse 71 market data Tables ...
(Date:7/13/2014)... 13, 2014 A Massachusetts couple who ... cancer risks associated with power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ) ... to federal regulators, as they presented poignant testimony on ... Drug Administration (FDA) advisory panel meeting convened to address ... the Rochester Democrat and Chronicle, Dr. Hooman Noorchashm and ...
(Date:7/13/2014)... 2014 The Pearland, Texas location of The ... from four months to 12 years of age that offers ... birthday parties and Summer Camps, is now under new ownership. ... Pearland after spending over six years at The Little ... Director. , Berry has over ten years of experience ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 The federal ... ) filed against Johnson & Johnson’s Ethicon, ... trial, which is expected to get underway next month. ... the U.S. District Court, Southern District of West Virginia ... held on August 7, 2014 at 3:00 p.m. July ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Max ... Famer, Chris Mullin, will be the featured guest at ... 26th in Puerto Rico. Attendees will learn about ... participate in two exhibition basketball games and perform in ... supplier of health- and energy-boosting supplements , has ...
Breaking Medicine News(10 mins):Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 4Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 4
... , , , ... http://www.avacor.com ) has acquired the assets ... name; Avacor,s FDA approved Physicians, Topical Formulation(R); the All-Natural Nutricap and ... Application) which allows the company to market and sell the FDA ...
... Going out like a brilliant flame is one way ... a form of programmed suicide called apoptosis, a desired effect ... could more quickly pick the most effective treatment. Now scientists ... way to do just that, by lighting up cells as ...
... A new study by researchers from the Automotive Safety Program ... Medicine published online July 13, 2009 in the journal ... health care needs are doing a good job with the ... help in using it correctly. The study, one of ...
... to aid in understanding childhood brain development and healthy ... Deficit Hyperactivity Disorder and detecting the early onset of ... million in recent funding from the Canadian Institutes of ... makes us human is the ability to control our ...
... , , WASHINGTON, July 13 ... creation of a National Diabetes Coordinator to develop and implement a nationwide ... , , A study commissioned by NCDP ... The coordinator would be responsible for establishing priorities in the fight ...
... , , , WASHINGTON, ... in Congress, the Institute for America,s Future today released the names ... All the experts favor a public health insurance option to compete with ... to the health care debate. , , ...
Cached Medicine News:Health News:Avacor(R), Premier Provider of Hair Growth Solutions, Acquired By Investor Group. 2Health News:Fluorescent probes may permit monitoring of chemotherapy effectiveness, Stanford study shows 2Health News:Fluorescent probes may permit monitoring of chemotherapy effectiveness, Stanford study shows 3Health News: Making the difficult task of transporting a child with special needs safer 2Health News:Queen's University study aims at early diagnosis for ADHD and Parkinson's disease 2Health News:Diabetes Advocates Call For National Strategy, Leadership to Reduce Diabetes and Advance Detection and Treatment 2Health News:Diabetes Advocates Call For National Strategy, Leadership to Reduce Diabetes and Advance Detection and Treatment 3Health News:Diabetes Advocates Call For National Strategy, Leadership to Reduce Diabetes and Advance Detection and Treatment 4Health News:Prominent Health Experts Who Support Public Insurance Option Available for Interview 2Health News:Prominent Health Experts Who Support Public Insurance Option Available for Interview 3Health News:Prominent Health Experts Who Support Public Insurance Option Available for Interview 4Health News:Prominent Health Experts Who Support Public Insurance Option Available for Interview 5
Inquire...
Integrated closure system provides security you can feel as the plastic fasteners lock into place and is both easy to close, empty and clean....
Flextend is a hydrocolloid skin barrier that is designed to be the most resistant to discharge and is the barrier of choice for urostomies and high output ileosotomies....
Inquire...
Medicine Products: